Sex-specific pathway driving melanoma metastasis discovered, with implications across female cancer treatments

Sex-specific pathway driving melanoma metastasis discovered, with implications across female cancer treatments

Publication date: Jun 24, 2025

They compared melanoma development and progression in mice with and without functional E-cadherin, across sexes. Results showed no difference in initial melanoma onset or primary tumor growth. Editors have highlighted the following attributes while ensuring the content’s credibility:a) In primary melanoma, the loss of CDH1 activates -catenin signaling, subsequently triggering the upregulation of ESR1. c) ECADneg/GRPRpos melanoma cells gain the ability to disseminate through the bloodstream to distant organs, notably the lungs, where GRP is produced in abundance. b) ECADneg/GRPRpos cancer cells grow in tissues expressing naturally GRP including lung, breast and gastric tissue. You’ll get an ad-free account as a thank-you. More information: Jrmy H. Raymond et al, Targeting GRPR for sex hormone-dependent cancer after loss of E-cadherin, Nature (2025). Activated GRPR increased cell growth, resistance to cell death (anoikis), and invasivenessall key processes required for metastasis. In normal cells, E-cadherin restricts the transcriptional activity of -catenin. When E-cadherin is lost, -catenin activates the ER gene (ESR1), whose protein indirectly enhances GRPR expression.

Concepts Keywords
Authors Cadherin
Cancer Cancers
Pharmacological Catenin
Grpr
Hormone
Loss
Melanoma
Metastasis
Nature
Pathway
Receptor
Sex
Specific
Women

Semantics

Type Source Name
disease MESH breast cancer
pathway KEGG Breast cancer
drug DRUGBANK Fulvestrant
disease MESH cancer
disease MESH melanoma
pathway KEGG Melanoma
disease MESH metastasis

(Visited 6 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *